Trials / Completed
CompletedNCT00750386
Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas
Dose Dense Administration of Paclitaxel and Carboplatin Combination as 1st Line Treatment in Patients With Ovarian Carcinoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Hellenic Oncology Research Group · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial will determine the feasibility and toxicity of dose intense (every 2 weeks) of paclitaxel+carboplatin combination following cytoreductive surgery in patients with stage Ic-IV ovarian cancer.
Detailed description
Dose dense chemotherapy has been proven beneficial in various oncological settings. It is proposed that this concept be tested in ovarian cancer, with the support of growth factors. It is hypothesized that, if feasible, dose-dense chemotherapy may be more effective.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paclitaxel | 175 mg/m2, I.V, every 2 weeks |
| DRUG | Carboplatin | Carboplatin AUC, I.V, 5 every 2 weeks |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2011-03-01
- Completion
- 2011-03-01
- First posted
- 2008-09-10
- Last updated
- 2011-05-23
Locations
12 sites across 1 country: Greece
Source: ClinicalTrials.gov record NCT00750386. Inclusion in this directory is not an endorsement.